NCT07291921Recruiting
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
This project aims to innovatively integrate multi-omics data, including plasma metabolomics, radiomics, and cfDNA multi-level information, combined with survival data (e.g., RFS), to establish a novel multidimensional approach for noninvasive postoperative recurrence monitoring in lung cancer using artificial intelligence algorithms. The goal is to develop a new noninvasive recurrence monitoring system for lung cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 6 Dec 2025
- Start date
- 8 May 2025
- Primary completion date
- 31 Oct 2027
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07291921
What you commit to
- Study type: Observational
- Planned participants: 100
- From 8 May 2025 to the primary completion date, 31 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindication to surgery preventing radical resection.
- Non-radical (R2) resection.
Other illness
- History of any malignancy within the past 5 years.
- Any condition deemed unsuitable by the investigator (e.g., perioperative blood transfusion, severe psychiatric disorder precluding follow-up).
Other
- Postoperative pathology shows other than NSCLC, including but not limited to benign lesions, small-cell carcinoma, metastasis, or indeterminate/inadequate histology.
- Insufficient or poor-quality blood or tissue samples.
- Pure ground-glass nodule on imaging.
- Pathologic stage IIIB-N3, IIIC, or IV on paraffin sections.
- Refusal or withdrawal of informed consent.
Who the study is looking for
- Signed written informed consent.
- Male or female, aged ≥ 18 and \< 85 years.
- Radical resection performed, pathologic stage IB-IIIA (8th TNM) non-small-cell lung cancer.
- Tumor tissue and blood samples obtainable at all protocol-specified time-points.
- No pure ground-glass nodule on imaging.
- Completed standard neoadjuvant immunotherapy combined with platinum-based chemotherapy.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.